NYSE:NUVB Nuvation Bio (NUVB) Stock Price, News & Analysis $2.24 -0.03 (-1.10%) As of 01:03 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends About Nuvation Bio Stock (NYSE:NUVB) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Nuvation Bio alerts:Sign Up Key Stats Today's Range$2.24▼$2.3350-Day Range$2.22▼$3.2252-Week Range$1.67▼$4.16Volume655,771 shsAverage Volume2.32 million shsMarket Capitalization$755.60 millionP/E RatioN/ADividend YieldN/APrice Target$8.20Consensus RatingBuy Company OverviewNuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutic candidates for oncology. The company's lead product candidate is NUV-868, a BD2 selective oral small molecule BET inhibitor that epigenetically regulates proteins that control tumor growth and differentiation, including oncogenes comprising c-myc; NUV-1156, an AR binder Xtandi that address advanced stage prostate cancers with the potential to move into earlier lines typically treated with surgical prostatectomy; and drug-drug conjugate (DDC) platform which leverages a novel therapeutic approach within the drug-conjugate class of anti-cancer therapies to deliver anti-cancer therapeutics to cancer cells, as well as NUV-1176, a PARP inhibitor to address ER+ breast and ovarian cancer. The company was founded in 2018 and is headquartered in New York, New York.Read More… Nuvation Bio Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks44th Percentile Overall ScoreNUVB MarketRank™: Nuvation Bio scored higher than 44% of companies evaluated by MarketBeat, and ranked 659th out of 950 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingNuvation Bio has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 5 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageNuvation Bio has only been the subject of 3 research reports in the past 90 days.Read more about Nuvation Bio's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Nuvation Bio are expected to decrease in the coming year, from ($0.36) to ($0.64) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Nuvation Bio is -1.04, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Nuvation Bio is -1.04, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioNuvation Bio has a P/B Ratio of 0.82. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Nuvation Bio's valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted11.00% of the float of Nuvation Bio has been sold short.Short Interest Ratio / Days to CoverNuvation Bio has a short interest ratio ("days to cover") of 9.7.Change versus previous monthShort interest in Nuvation Bio has recently increased by 14.33%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldNuvation Bio does not currently pay a dividend.Dividend GrowthNuvation Bio does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted11.00% of the float of Nuvation Bio has been sold short.Short Interest Ratio / Days to CoverNuvation Bio has a short interest ratio ("days to cover") of 9.7.Change versus previous monthShort interest in Nuvation Bio has recently increased by 14.33%, indicating that investor sentiment is decreasing significantly. News and Social Media2.4 / 5News Sentiment1.38 News SentimentNuvation Bio has a news sentiment score of 1.38. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.60 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Nuvation Bio this week, compared to 3 articles on an average week.Search InterestOnly 2 people have searched for NUVB on MarketBeat in the last 30 days. This is a decrease of -60% compared to the previous 30 days.MarketBeat FollowsOnly 5 people have added Nuvation Bio to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days. Company Ownership1.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Nuvation Bio insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 5.07% of the stock of Nuvation Bio is held by insiders.Percentage Held by Institutions61.67% of the stock of Nuvation Bio is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Nuvation Bio's insider trading history. Receive NUVB Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Nuvation Bio and its competitors with MarketBeat's FREE daily newsletter. Email Address NUVB Stock News HeadlinesKuehn Law Encourages Investors of Nuvation Bio Inc. to Contact Law FirmFebruary 18 at 1:49 PM | prnewswire.comNuvation Bio: Pending Approval Shot In ROSL+ NSCLS Looks A Major Upside CatalystFebruary 13, 2025 | seekingalpha.com9/9 on TSLA from June to JanuaryPlease take a look at THIS case study on Target (TGT) You’ll see exactly how the tool works to trade long and short, even when the markets seem to be predicting the exact opposite. Now, this tool has been so accurate over recent months that I’m planning to send you 14 more real-world examples of winning trades that anyone using this tool could have captured. And it’s all building to Monday, February 24 @ 1pm ET when I’ll bring the tool to the public for the first time and show you how you can put it on your own charts!February 21, 2025 | Wealthpin Pro (Ad)Nuvation Bio executive departs after key milestonesFebruary 12, 2025 | msn.comKuehn Law Encourages Investors of Nuvation Bio Inc. to Contact Law FirmFebruary 12, 2025 | investing.comNuvation Bio launches EAP for lung cancer drug taletrectinibFebruary 3, 2025 | msn.comNuvation Bio Announces Expanded Access Program in the U.S. for Taletrectinib in Advanced ROS1-positive Non-Small Cell Lung CancerFebruary 3, 2025 | finance.yahoo.comNuvation Bio begins EAP for taletrectinib in US for advanced ROS1 + NSCLCFebruary 3, 2025 | markets.businessinsider.comSee More Headlines NUVB Stock Analysis - Frequently Asked Questions How have NUVB shares performed this year? Nuvation Bio's stock was trading at $2.66 at the beginning of 2025. Since then, NUVB shares have decreased by 14.8% and is now trading at $2.2650. View the best growth stocks for 2025 here. How were Nuvation Bio's earnings last quarter? Nuvation Bio Inc. (NYSE:NUVB) released its quarterly earnings data on Wednesday, November, 6th. The company reported ($0.15) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.13) by $0.02. The business had revenue of $0.73 million for the quarter. Who are Nuvation Bio's major shareholders? Top institutional investors of Nuvation Bio include FMR LLC (13.46%), Vanguard Group Inc. (4.67%), Geode Capital Management LLC (1.47%) and MPM Bioimpact LLC (1.24%). Insiders that own company stock include Fund V LP Omega, Oleg Nodelman, Xiangmin Cui and Robert Mashal. View institutional ownership trends. How do I buy shares of Nuvation Bio? Shares of NUVB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Nuvation Bio own? Based on aggregate information from My MarketBeat watchlists, some other companies that Nuvation Bio investors own include Humana (HUM), American Water Works (AWK), Voyager Therapeutics (VYGR), Waste Connections (WCN), The RMR Group (RMR), AUO (AUOTY) and DiamondRock Hospitality (DRH). Company Calendar Last Earnings11/06/2024Today2/21/2025Next Earnings (Estimated)5/12/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSE SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNYSE:NUVB CUSIPN/A CIK1811063 Webwww.nuvationbio.com Phone332-208-6102FaxN/AEmployees60Year FoundedN/APrice Target and Rating Average Stock Price Target$8.20 High Stock Price Target$11.00 Low Stock Price Target$5.00 Potential Upside/Downside+262.0%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage5 Analysts Profitability EPS (Most Recent Fiscal Year)($2.17) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-75,800,000.00 Net MarginsN/A Pretax Margin-24,619.84% Return on Equity-21.89% Return on Assets-17.86% Debt Debt-to-Equity RatioN/A Current Ratio9.57 Quick Ratio9.57 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$2.76 per share Price / Book0.82Miscellaneous Outstanding Shares336,570,000Free Float319,503,000Market Cap$762.33 million OptionableOptionable Beta1.45 7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleLooking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.Get This Free Report This page (NYSE:NUVB) was last updated on 2/21/2025 by MarketBeat.com Staff From Our PartnersCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredNVDA Crash UpdateAn overseas AI rival sent shockwaves through the U.S. tech market last week... Leaving millions of investor...Chaikin Analytics | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | Sponsored My 2025 AI BlueprintI first recommended Bitcoin at $300 in 2013 … before it went up 33,645%. Now, I am revealing my 2025 AI Blu...Weiss Ratings | Sponsored Is Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again ...Paradigm Press | SponsoredBuy this AI Stock Before Elon’s AnnouncementWith Trump back in office, xAI is primed to become the leader in generative AI, leaving competitors in the dus...InvestorPlace | SponsoredElon’s “New Gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Nuvation Bio Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Nuvation Bio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.